CagriSema is a fixed-dose combination therapy comprising two molecules administered together in a single once-weekly subcutaneous injection: semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist already approved for weight management as Wegovy, and cagrilintide 2.4 mg, a long-acting analogue of amylin, a hormone involved in appetite regulation and satiety signalling
We are committed to breaking down barriers and making weight loss a possibility for all
Research has used MT-1 to characterise these melanin-independent photoprotection mechanisms and establishing that MC1R activation provides a layer of cellular UV protection through DNA repair enhancement and oxidative stress reduction thats distinct from and additive to the physical UV-screening function of melanin pigmentation
It helps to view these as a progression in medical science
Clinical evidence suggests that whilst these medicines do not directly damage the eyes, they may be associated with worsening diabetic retinopathy in certain patients, particularly those with pre-existing eye disease who experience rapid improvements in blood glucose control
microdosing begins at lower doses of 1.5 mg for women and 1.8 mg for men
